Skip to main content
. 2022 May 25;8(6):e09538. doi: 10.1016/j.heliyon.2022.e09538

Table 3.

Clinical response according to RECIST1.1

Group1 (n = 54) Group2 (n = 85) χ2 P value
ORR 18/54 (33.30%) 21/85 (24.70%) 1.110 0.292
DCR 47/54 (87.00%) 63/85 (74.10%) 0.089 0.765

Group1, lenvatinib plus sintilimab treatment group; Group2, lenvatinib monotherapy group.

Objective response rate (ORR); Disease Control Rate (DCR).